Wells Fargo’s Alterity Therapeutics ATHE Stock Holding History
Bought
Maintained
Sold
Other funds holding ATHE
PFGI
Wells Fargo's ATHE Position: Q3 2026 in Review
Wells Fargo opened a new position in Alterity Therapeutics (ATHE) in Q3 2026: 100 shares worth $365. The stake represents ﹤0.01% of the portfolio and ranks #6570 among its holdings. This is a return to the name: Wells Fargo previously reported a position in ATHE as recently as Q3 2021.
Wells Fargo first reported a position in ATHE in Q2 2013 and has held it in 31 quarters since. The position peaked at $35K in Q4 2013. 22 funds tracked by Wall St. Rank hold ATHE as of Q3 2026.
- Wells Fargo held 100 shares of Alterity Therapeutics worth $365 as of Q3 2026.
- Alterity Therapeutics was a new Wells Fargo position in Q3 2026.
- Alterity Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #6570 holding.
- Wells Fargo first reported a position in Alterity Therapeutics in Q2 2013 and has held it in 31 quarters since.
- Wells Fargo's Alterity Therapeutics position peaked at $35K in Q4 2013.
- 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.